Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 107Lymphoma 48Lymphoma, Non-Hodgkin 44Hodgkin Disease 44Leukemia, Myeloid, Acute 41Myelodysplastic Syndromes 40Leukemia 34Precursor Cell Lymphoblastic Leukemia-Lymphoma 33Leukemia, Lymphocytic, Chronic, B-Cell 28Lymphoma, Mantle-Cell 26Neoplasms, Plasma Cell 25Lymphoma, Large B-Cell, Diffuse 24Lymphoma, Follicular 24Lymphoma, B-Cell, Marginal Zone 18Burkitt Lymphoma 18Leukemia, Myelogenous, Chronic, BCR-ABL Positive 17Myeloproliferative Disorders 16Recurrence 14Immunoglobulin Light-chain Amyloidosis 14Congenital Abnormalities 13Primary Myelofibrosis 12Lymphoma, Large-Cell, Immunoblastic 12Leukemia, Myeloid, Accelerated Phase 12Hematologic Neoplasms 12Waldenstrom Macroglobulinemia 10Lymphoma, T-Cell, Cutaneous 10Leukemia, Myelomonocytic, Juvenile 10Leukemia, Myelomonocytic, Chronic 10Leukemia, Myeloid, Chronic-Phase 10Dendritic Cell Sarcoma, Interdigitating 10

Interventions

Ipilimumab 10tremelimumab 6durvalumab 5Nivolumab 3pembrolizumab 2tilsotolimod 1spartalizumab 1relatlimab 1folfirinox 1balstilimab 1Vemurafenib 1Vaccines 1Radiotherapy 1Radiofrequency Ablation 1Radiation 1Paclitaxel 1Oxaliplatin 1Opdualag 1Melphalan 1Leucovorin 1Fluorouracil 1Docetaxel 1Cryosurgery 1Carboplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Diabetes Mellitus, Insulin-Dependent, 12 × Melphalan × Clear all
NCT02716805 2022-10-12

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

Ludwig Institute for Cancer Research

Phase 1 Terminated
6 enrolled 11 charts
Plasma cell

Diabetes Mellitus, Insulin-Dependent, 12, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡